Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 1:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 192 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Heart failure or coronary disease Clear all
Completed Phase 2 Interventional Results available

Study of High-dose Spironolactone vs. Placebo Therapy in Acute Heart Failure

NCT02235077
View directory record Official record
Conditions
Heart Failure
Interventions
Spironolactone, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
21 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
22
States / cities
Atlanta, Georgia • Baltimore, Maryland • Boston, Massachusetts + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 10, 2026, 1:32 PM EDT
Completed No phase listed Observational

A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

NCT03492580
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Cardiovascular Diseases
Interventions
Canagliflozin, Empagliflozin, Dapagliflozin, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Glucagon-like Peptide-1 (GLP-1) Agonist, Anti-hyperglycemic Agents (AHA), Thiazolidinediones (TZD), Sulfonylureas (SU), Insulin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
714,582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Titusville, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 10, 2026, 1:32 PM EDT
Suspended Phase 1 Interventional

Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines

NCT02962661
View directory record Official record
Conditions
Cardiomyopathy, Heart Failure, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Best Practice, Laboratory Biomarker Analysis, Mesenchymal Stem Cell Transplantation
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 10, 2026, 1:32 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Cor360: Clinician-Facing Broad-Spectrum Cardiac Phenotyping and Risk Assessment Using COR® Wearable ECG to Inform Outcomes-Oriented Care Pathways

NCT07775976
View directory record Official record
Conditions
Cardiovascular Diseases, Cardiovascular Diseases Risk, Cardiac Conduction System Disease, Bundle/Fascicular Abnormalities, His-Purkinje Disease, Arrhythmias, Cardiac, Rhythm Phenotypes, Myocardial Ischemia, Syncope, Syncope Recurrent, Syncope and Collapse, Seizure Disorder, Sleep Apnea Syndrome, Obstructive, Decision Support Systems, Clinical, Heart Failure - NYHA II - IV, Heart Failure (for Example, Fluid Overload), HRV, Cardiopulmonary, Sudden Cardiac Arrest, Cardiac Arrest (CA), Ventricular Arrhythmias and Cardiac Arrest, Ventricular Fibrillation, QT Dispersion, Atrial Cardiomyopathy
Interventions
COR Wearable ECG Monitoring, Cor360 Clinician-Facing Decision-Aid Reporting
Device · Other
Lead sponsor
Peerbridge Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
2
States / cities
Pasadena, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 10, 2026, 1:32 PM EDT
Recruiting Phase 4 Interventional

Epicardial Adipose Tissue Composition and Heart Failure With Preserved Ejection Fraction

NCT07178145
View directory record Official record
Conditions
Heart Failure Preserved Ejection Fraction, Epicardial Adipose Tissue
Interventions
GLP-1RA
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 90 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 10, 2026, 1:32 PM EDT
Completed Phase 2 Interventional Results available

Non-Invasive Diagnosis of Pulmonary Vascular Disease Using Inhaled 129Xe Magnetic Resonance Imaging

NCT03078192
View directory record Official record
Conditions
Pulmonary Vascular Disease
Interventions
GE-141, Hyperpolarized 129Xenon gas, MRI
Drug · Device
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced Oct 10, 2026, 1:32 PM EDT
Recruiting Not applicable Interventional

ELEVATE-HFpEF Clinical Study

NCT06678841
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions
Personalized cardiac pacing
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
40 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
26
States / cities
Phoenix, Arizona • Palo Alto, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 10, 2026, 1:32 PM EDT
Completed Not applicable Interventional

Helping Others Toward Positive Emotions in People With Heart Failure

NCT01275742
View directory record Official record
Conditions
Heart Failure
Interventions
Brief Cognitive Therapy Intervention
Behavioral
Lead sponsor
Rebecca L. Dekker, PhD, RN, APRN
Other
Eligibility
21 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 11, 2017 · Synced Oct 10, 2026, 1:32 PM EDT
Completed Not applicable Interventional Results available

NHLBI DIR LAMPOON Study: Intentional Laceration of the Anterior Mitral Leaflet to Prevent Left Ventricular Outflow Tract Obstruction During Transcatheter Mitral Valve Implantation

NCT03015194
View directory record Official record
Conditions
Mitral Valve Failure
Interventions
Edwards SAPIEN 3 transcatheter heart valve, ASHI INTECC Astato XS 20
Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
21 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Oct 10, 2026, 1:32 PM EDT
Completed Phase 4 Interventional Results available

Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients With Severe Kidney Disease Undergoing Myocardial Perfusion Imaging

NCT01336140
View directory record Official record
Conditions
Patients With Severe Chronic Kidney Disease Being Evaluated With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson
Interventions
Aminophylline, Placebo
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Oct 10, 2026, 1:32 PM EDT
Completed Not applicable Interventional

Resistance Training in HFpEF

NCT02435667
View directory record Official record
Conditions
Heart Failure Preserved Ejection Fraction
Interventions
Resistance Exercise Training, DEXA bone scan, Cardiopulmonary Max Exercise Test, Quality of Life Questionnaire, Submaximal Exercise Test, Blood Draw
Other · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 10, 2026, 1:32 PM EDT
Recruiting Not applicable Interventional

The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)

NCT05427370
View directory record Official record
Conditions
Coronary Artery Disease, Heart Failure Systolic
Interventions
Revascularization by PCI, Revascularization by CABG
Procedure
Lead sponsor
Sunnybrook Health Sciences Centre
Other
Eligibility
18 Years and older
Enrollment
754 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
6
States / cities
Los Angeles, California • New Haven, Connecticut • Louisville, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 10, 2026, 1:32 PM EDT
Not listed Not applicable Interventional

Caisson Transcatheter Mitral Valve Replacement (TMVR)

NCT03661398
View directory record Official record
Conditions
Mitral Regurgitation, Mitral Valve Disease, Mitral Valve Failure, Mitral Disease, Valve Heart Disease, Valve Disease, Heart
Interventions
Transcatheter Mitral Valve Replacement
Device
Lead sponsor
Caisson Interventional LLC
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Oct 10, 2026, 1:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Systolic Blood Pressure Intervention Trial

NCT01206062
View directory record Official record
Conditions
Hypertension
Interventions
Intensive control of SBP, Standard control of SBP
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
50 Years and older
Enrollment
9,361 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 8, 2021 · Synced Oct 10, 2026, 1:32 PM EDT
Completed Not applicable Interventional Results available

REALIsM-HF Pilot Study

NCT03507439
View directory record Official record
Conditions
Heart Failure
Interventions
AVIVO Mobile Patient Management (MPM) System, VitalPatch biosensor, DynaPort Move Monitor
Device
Lead sponsor
Bayer
Industry
Eligibility
45 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 10, 2026, 1:32 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neurotoxicity and Cardiotoxicity in Total Joint Arthroplasty

NCT04166539
View directory record Official record
Conditions
Metallosis, Pain, Total Hip Replacement, Total Knee Replacement
Interventions
Questionnaires, Interviews, Blood draw, Magnetic Resonance Imaging, Echocardiogram
Behavioral · Other · Radiation + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 100 Years
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced Oct 10, 2026, 1:32 PM EDT
Not yet recruiting Not applicable Interventional

CGM Use in Heart Failure

NCT07045298
View directory record Official record
Conditions
Heart Failure, Diabetes Mellitus
Interventions
Libre 2 rt-CGM, POC BG + Blinded CGM
Device · Diagnostic Test
Lead sponsor
Emory University
Other
Eligibility
18 Years to 90 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 10, 2026, 1:32 PM EDT
Completed No phase listed Observational

Genetic and Environmental Determinants That Control Metabolism in Pulmonary Hypertension

NCT02594917
View directory record Official record
Conditions
Iron-sulfur Cluster Deficiency, Pulmonary Hypertension, Friedreich Ataxia
Interventions
Right Heart Catheterization, Blood draw
Procedure · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 60 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 22, 2023 · Synced Oct 10, 2026, 1:32 PM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Safety and Efficacy of Alefacept (Amevive) in Subjects With Moderate to Severe Atopic Dermatitis

NCT00832585
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Alefacept
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 10, 2011 · Synced Oct 10, 2026, 1:32 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Supporting Health in Veterans With Heart Failure

NCT05839067
View directory record Official record
Conditions
Heart Failure
Interventions
Care-HF
Behavioral
Lead sponsor
Florida State University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
4
States / cities
Gainesville, Florida • Togus, Maine • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Oct 10, 2026, 1:32 PM EDT
Terminated Not applicable Interventional Results available

Timing of PDA Closure and Respiratory Outcome in Premature Infants

NCT00802685
View directory record Official record
Conditions
Patent Ductus Arteriosus
Interventions
Early ibuprofen, Late ibuprofen expectant group (placebo)
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
1 Day to 14 Days
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 5, 2014 · Synced Oct 10, 2026, 1:32 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%

NCT04435626
View directory record Official record
Conditions
Heart Failure
Interventions
Finerenone (BAY94-8862), Placebo
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
40 Years and older
Enrollment
6,016 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
107
States / cities
Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 98 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 10, 2026, 1:32 PM EDT
Active, not recruiting Not applicable Interventional

The TRIABETES - ARMMS-T2D Study: A Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes

NCT01047735
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Obesity
Interventions
Roux-en-Y Gastric Bypass Surgery, Laparoscopic Adjustable Gastric Banding, Lifestyle Weight Loss Intervention
Procedure · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
25 Years to 55 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 10, 2026, 1:32 PM EDT
Completed Phase 2 Interventional Results available

Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone

NCT01807221
View directory record Official record
Conditions
Heart Failure
Interventions
Finerenone (BAY94-8862), Placebo, Inspra (eplerenone)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,066 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
10
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Oct 10, 2026, 1:32 PM EDT